The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report by Neogi, Tuhina et al.
ARTHRITIS & RHEUMATISM
Vol. 62, No. 9, September 2010, pp 2582–2591
DOI 10.1002/art.27580
© 2010, American College of Rheumatology
The 2010 American College of Rheumatology/
European League Against Rheumatism
Classification Criteria for Rheumatoid Arthritis
Phase 2 Methodological Report
Tuhina Neogi,1 Daniel Aletaha,2 Alan J. Silman,3 Raymond L. Naden,4 David T. Felson,1
Rohit Aggarwal,5 Clifton O. Bingham, III,6 Neal S. Birnbaum,7 Gerd R. Burmester,8
Vivian P. Bykerk,9 Marc D. Cohen,10 Bernard Combe,11 Karen H. Costenbader,12
Maxime Dougados,13 Paul Emery,14 Gianfranco Ferraccioli,15 Johanna M. W. Hazes,16
Kathryn Hobbs,17 Tom W. J. Huizinga,18 Arthur Kavanaugh,19 Jonathan Kay,20
Dinesh Khanna,21 Tore K. Kvien,22 Timothy Laing,23 Katherine Liao,12 Philip Mease,24
Henri A. Ménard,25 Larry W. Moreland,5 Raj Nair,26 Theodore Pincus,27 Sarah Ringold,28
Josef S. Smolen,2 Ewa Stanislawska-Biernat,29 Deborah Symmons,30 Paul P. Tak,31
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Objective. The American College of Rheumatology and the European League Against Rheumatism have
developed new classification criteria for rheumatoid
arthritis (RA). The aim of Phase 2 of the development
process was to achieve expert consensus on the clinical
and laboratory variables that should contribute to the
final criteria set.
Methods. Twenty-four expert RA clinicians (12
from Europe and 12 from North America) participated
in Phase 2. A consensus-based decision analysis ap-
proach was used to identify factors (and their relative
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weights) that influence the probability of “developing
RA,” complemented by data from the Phase 1 study.
Patient case scenarios were used to identify and reach
consensus on factors important in determining the
probability of RA development. Decision analytic soft-
ware was used to derive the relative weights for each of
the factors and their categories, using choice-based
conjoint analysis.
Results. The expert panel agreed that the new
classification criteria should be applied to individuals
with undifferentiated inflammatory arthritis in whom
at least 1 joint is deemed by an expert assessor to be
swollen, indicating definite synovitis. In this clinical
setting, they identified 4 additional criteria as being
important: number of joints involved and site of involve-
ment, serologic abnormality, acute-phase response, and
duration of symptoms in the involved joints. These
criteria were consistent with those identified in the
Phase 1 data-driven approach.
Conclusion. The consensus-based, decision analy-
sis approach used in Phase 2 complemented the Phase 1
efforts. The 4 criteria and their relative weights form the
basis of the final criteria set.
The new American College of Rheumatology/
European League Against Rheumatism (ACR/EULAR)
classification criteria for rheumatoid arthritis (RA) were
developed in 3 phases (1). Phase 1, led by the EULAR
(AS and DA), used cohort data to identify the key
factors to be considered in the new criteria, and their
associated weights (2). The current report outlines the
second phase, led by the ACR (TN, DF, and GH). A
consensus-based, decision science–informed approach
was used to identify factors that influence expert RA
clinicians’ opinions about the probability of developing
persistent inflammatory or erosive arthritis (“developing
RA”). The rationale for this approach was 2-fold: to
ensure that expert clinicians’ perspectives were cap-
tured, and to ensure that potentially important factors
not captured in the Phase 1 cohort data might be
identified. Results from Phases 1 and 2 were subse-
quently integrated to determine the final criteria set (1).
METHODS
Phase 2 included the following steps: 1) assembly of an
expert panel, 2) development and rank ordering of patient case
scenarios, 3) a 2-day in-person consensus meeting, and 4)
assessment of face and construct validity.
The expert panel. With input from the ACR and
EULAR leadership, equal numbers of North American and
European expert clinical rheumatologists were selected. The
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expert panel included community and academic rheumatolo-
gists, and was diverse in terms of geography and numbers of
men and women.
Development of patient case scenarios. Expert panel
members used a standardized template (Supplementary Figure
1, available in the online version of this article at http://
www3.interscience.wiley.com/journal/76509746/home) to sub-
mit 3–5 real-life case scenarios representing patients with early
(within 1 year of symptom onset) undifferentiated inflamma-
tory arthritis. These scenarios included all patient information
that the experts considered relevant to rule in (positive factors)
or out (negative factors) an eventual diagnosis of RA.
Each scenario captured the following patient elements:
age and sex, duration of joint pain, duration of joint swelling,
average duration of morning stiffness, and distribution of
affected joints (swollen and tender joints, indicated on joint
homunculi). The expert also provided information on the
subsequent disease course, whether or not treatment with
methotrexate (MTX) had been initiated at that assessment
time point, and the expert’s opinion, using a 5-point Likert
scale from 1 (very low probability) to 5 (very high probability),
of the probability that the patient would, if untreated, “develop
RA.”
Each completed case scenario was assigned a unique
name. Two members of the steering committee (TN and GH)
selected a subset of 30 case scenarios that best represented the
spectrum of probability of RA development. Most of the cases
were in the middle 3 probability categories. These 30 scenarios
were then simplified and standardized. The submitting expert’s
identity, opinion regarding the probability of RA, and infor-
mation on the subsequent disease course were removed.
Rank ordering of case scenarios by the expert panel.
Following review of the Phase 1 study results (2), expert panel
members rank ordered the 30 cases, from 1 (highest probabil-
ity of developing RA), to 30 (lowest probability). Additionally,
for each case, the expert panel members indicated whether
they would initiate treatment with MTX (yes or no, assuming
that there were no contraindications and the patient was
agreeable). The mean and distribution of rankings for each
case scenario and for each expert panel member were plotted.
In-person consensus meeting. The expert panel met
for 2 days in May 2009. The meeting was facilitated by RLN, an
internist from Auckland, New Zealand who has expertise in
consensus conferencing and use of decision analytic software
(3).
Identification of domains, categories, and weights.
Members of the expert panel were presented their case
rankings, and in-depth group discussion of potential reasons
for lack of agreement identified key positive and negative
factors that were important in evaluating patients’ probability
of developing RA. Evidence from both Phase 1 study data and
published data, as available, was used to support the discus-
sions and decisions. After the panelists identified a list of key
factors, the ones deemed most important and essential were
agreed upon. These essential factors or criteria form the basis
of the final criteria set. They then defined specific categories
within each criterion that signified different levels of probabil-
ity. For example, for pattern and extent of joint involvement, a
hierarchy of a combination of number and type of involved
joints defined the various categories within that criterion,
signifying increasing levels of probability of developing RA.
Since the resulting criteria and their respective catego-
ries produce multiple possible combinations of clinical features,
decision analytic software (1000Minds [www.1000minds.com])
was used to facilitate the quantification of the relative impor-
tance or “weight” for each criterion and category. The decision
analytic software program used choice-based conjoint analysis
(sometimes referred to as “discrete choice experiments” or
“multi-criteria decision analysis”) to evaluate, through discrete
pairwise choices, the weights attached to the categories within
each criterion. This approach has been used successfully in
other projects (4–8), for example to enumerate factors affect-
ing urgency of need for referral to rheumatologists for acute
rheumatic conditions. The pairwise ranking employed by this
methodology is a natural human activity that people experi-
ence in their daily lives. Deciding between just 2 alternatives is
cognitively less burdensome, and therefore arguably more
valid and reliable, than alternative methods for eliciting pref-
erences to derive the weights. This method is more efficient
than others because any pairwise decisions in which one option
clearly has higher probability “RA development” (e.g., “high-
positive serology and 10 joints involved” has a higher prob-
ability than “low-positive serology and 1–3 small joints in-
volved”) are not presented for decision-making. Efficiency is
also gained by not requiring further discussion when there is
consensus. The program can also be administered over the
Internet, allowing for the process to be conducted without an
in-person meeting when necessary. A major advantage is that
individual categories can be modified, such as when new
information becomes available, and the weightings recalcu-
lated without disrupting the validity of the method or the
previous consensus decisions made.
An experienced facilitator guided the use of the soft-
ware program. The expert panel participants were presented a
series of paired scenarios, each comprising information rele-
vant to 2 different criteria. For each pair, they independently
and anonymously (using touch keypads) chose the scenario
they thought had the higher probability of “developing RA.”
Figure 1 shows an example in which case 1 has a lower level of
joint involvement and a higher level of abnormal serology,
while case 2 has the opposite. The distribution of opinions
(case 1 more likely to develop RA, case 2 more likely, equally
likely) was presented to the group and the reasons for dis-
agreement, if any, were discussed. The group then re-voted.
Consensus was considered achieved when all participants
either indicated agreement or indicated that they could accept
the majority decision.
Based on these discrete choices, the decision analytic
software program uses mathematical methods to determine
the relative importance, and thereby weight, of each category
within each criterion. The process is iterative, such that each
successive result further refines the weights derived through
prior choice outcomes. The final weights determine the scores
assigned to each category, and the sum of the weights produces
a total score for each case, from low to high probability. The
weights are scaled such that those associated with the highest
categories in each criterion sum to 100. Thus, possible scores
range from 0 to 100, with a higher score indicating a higher
probability of developing RA.
Assessment of the face validity of the weights. The next
step assessed whether the case rankings, achieved using the
“probability of developing RA” scores, reflected the experts’
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clinical judgment. Ten of the 30 case scenarios, representing
very low to very high probability of RA, were selected and
scored. The expert panel reviewed the rankings and discussed
cases that seemed out of place, based on clinical impression.
Where necessary, modifications were made to the criteria
categories to address concerns raised. The decision analytic
program was then used to reassign weights to the revised
categories, followed by scoring and re-review of the 10 case
rankings to confirm that concerns had been addressed.
Assessment of interrater reliability of scoring. At a
second in-person meeting, Phase 1 and Phase 2 participants
reviewed the results of the consensus meeting, further revised
and defined each of the criteria and criteria categories, and
outlined steps for validation. The 56 case scenarios not in-
cluded in the initial set of 30 were simplified, anonymized, and
assigned a unique name. The steering committee members and
2 volunteers who had not participated in the in-person con-
sensus meeting independently categorized each case within
each criterion to determine the consistency of categorization,
and thus ultimate scoring. By teleconference, the group dis-
cussed potential explanations for disagreements. Modifications
were made to the criteria or category definitions until full
consensus was achieved. These definitions were compiled in a
glossary.
Assessment of face and construct validity. Cases were
rank ordered from highest probability of developing RA (score
closest to 100) to lowest probability of developing RA (score
closest to 0). Phase 1 and 2 participants reviewed the rank
ordering to identify cases that were substantively out of place.
Additionally, for each case, the panelists indicated if they
would 1) treat with MTX or another disease-modifying anti-
rheumatic drug (DMARD) due to risk for developing RA
(yes/no) and 2) assuming eligibility, enroll the patient into a
clinical trial of an investigational biologic therapy with inherent
risks (yes/no).
RESULTS
Twenty-four expert rheumatologists (12 Euro-
pean, 12 North American) participated in Phase 2.
Among the North American rheumatologists, 25% were
female and 75% were in academic (as opposed to
community) practice; among the European rheumatolo-
gists, 25% were female and 50% were in academic
practice. The expert panelists submitted 86 patient case
scenarios in total. From these, 30 were chosen, simpli-
fied, standardized, anonymized, and rank ordered by the
expert panel based on panel members’ opinion of the
probability of developing RA. The distribution of rank-
ings, shown in Figure 2, indicated a relative lack of
consensus for most cases; some cases, e.g., case 14,
received the full range of probability rankings, from
highest to lowest.
Twenty-two of the 24 expert panel members
attended the in-person consensus meeting. Through
review of the expert panel rankings and the reasons for
disagreement, the following were identified as important
factors in determining the probability of developing RA:
expert determination of evidence of joint swelling, indi-
cating synovitis; morning stiffness; joint distribution
(site, number, symmetry); temporal evolution of joint
involvement; family history; age; sex; joint tenderness
versus swelling; features of another inflammatory arthri-
tis; physician global assessment; serology (anti–
citrullinated protein antibody [ACPA], and rheumatoid
factor [RF]); acute-phase response; duration of symp-
toms; duration of synovitis; and others. Each factor was
Figure 1. Example of a discrete choice experiment. RA  rheumatoid arthritis; RF  rheumatoid
factor; ACPA  anti–citrullinated protein antibody; MCPs  metacarpophalangeal joints; PIPs 
proximal interphalangeal joints; MTPs  metatarsophalangeal joints.
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discussed, and the evidence supporting its usefulness
reviewed. Further, all discussions about potential factors
for inclusion in the new classification criteria took into
account the ability of these criteria to be used through-
out the world, regardless of income level or health care
system. From these discussions, the expert panel identi-
fied the factors that should be incorporated in the new
classification criteria.
Identifying the population to which the new
criteria should be applied. To ensure that the classifica-
tion criteria are applied to persons with undifferentiated
inflammatory arthritis, the expert panel identified 2
mandatory criteria. First, there should be evidence, as
determined by an expert assessor, of swelling, indicating
synovitis, in at least 1 synovial joint, excluding joints
typically involved in osteoarthritis (distal interphalan-
geal [DIP] joints, first metatarsophalangeal [MTP] joint,
first carpometacarpal [CMC] joint). Second, signs and
symptoms must not be better explained by another
diagnosis. Thus, depending on the patient presentation
and context (e.g., sociodemographics and geographic
prevalence of specific conditions), if another definable
disease better explains the presence of synovitis, the new
RA criteria should not be applied.
Domains of importance for the new criteria set.
Assuming these 2 mandatory criteria were met, the
following additional criteria were identified as being
essential for determining the probability of developing
RA: pattern and extent of joint involvement, duration of
signs and symptoms of synovitis, serologic findings (ACPA
or RF), and acute-phase response (erythrocyte sedimen-
tation rate [ESR] or C-reactive protein [CRP] level).
Pattern and extent of joint involvement. Given the
mandatory requirement for expert-determined synovitis
(swelling) in at least 1 joint, the expert panel agreed that
this criterion should refer to the number and distribution
of “involved joints,” defined as tender or swollen joints
at the time of the physician assessment. Again, due to
concerns about overlap with osteoarthritis, the DIP, first
MTP, and first CMC joints should not be included. Six
categories associated with increasing probability of de-
veloping RA were determined within this criterion: 1)
monarthritis of a medium-large joint (shoulder, elbow,
hip, knee, or ankle); 2) at least 2 asymmetrically involved
medium-large joints; 3) at least 2 symmetrically involved
medium-large joints; 4) 1–3 involved small joints of the
hands and feet (metacarpophalangeal, proximal inter-
phalangeal, second through fifth MTP) or wrists; 5) 4
Figure 2. Initial rankings (IR) by the expert rheumatologist panel (n  24). Expert panel members
are indicated by colored dots.
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asymmetrically involved small joints of the hands and feet
or wrists; 6) 4 symmetrically involved small joints of the
hands and feet or wrists (Table 1). While a patient may
fulfill more than one category, the highest category of
fulfillment takes precedence for scoring.
Serology. The role of RF versus ACPA in deter-
mining probability of developing RA was reviewed.
First, recent literature reviews (9,10) indicate only small
systematic differences between ACPA and RF in pre-
dicting RA outcomes. Second, Phase 1 analyses did not
reveal any major differences between ACPA and RF (2).
Finally, the ultimate classification criteria must be appli-
cable for use internationally, including regions where
ACPA testing is not readily available. Thus, expert panel
members recommended that ACPA and RF comprise a
single criterion, “serology.” Since evidence indicates that
prognosis varies by level of both RF and ACPA (11), the
group agreed that the serology criterion should comprise
3 categories, with increasing probability of RA: abnor-
mal result on neither test, low-level positive result on at
least 1 test, or high-level positive result on at least 1 test
(Table 1). A task force (KHC, TWJH, HAM, JSS, and
PPT) was created to inform the definition of high and
low levels for RF and ACPA.
Acute-phase response. In Phase 1, ESR and CRP
had similar predictive validity for various RA outcomes.
Given insufficient evidence to support the use of multi-
ple cut points, panel members agreed that this criterion
should be represented by only 2 categories: normal
(abnormal result on neither test) or abnormal (elevation
of either CRP level or ESR or both), based on local
laboratory standards (Table 1).
Duration. Persistence of synovitis is associated
with prognosis. While most patients are currently as-
sessed for possible RA beyond 8 weeks of symptoms, the
intent of the new criteria is to encourage earlier referral,
diagnosis, and treatment. Thus, the criteria should be
applicable in early disease. Given the mandatory re-
quirement for expert-determined synovitis (swelling) in
at least 1 joint, the group agreed that “duration” of
synovitis should be assessed based on patient self-
reported signs or symptoms of synovitis (e.g., pain,
swelling, tenderness) of joints that are clinically “in-
volved,” as defined above, at the time of the physician
assessment. Three criterion categories were identified,
with increasing probability of RA: duration 4 weeks,
4–8 weeks, and 8 weeks (Table 1).
Refinement phase: the relative importance of
each domain and category. The resultant initial weights
for each of the 14 criteria categories are shown in Table
1. Using these weights, 10 of the 30 cases were scored
and the rank order presented to the expert panel. The
expert panel identified 2 cases that received an inappro-
priately low relative ranking; both cases had negative
serologic results in the setting of multiple small joints
involved. To address this, an additional “joint distribu-
tion” category was created: 10 joints involved, includ-
ing, but not limited to, small joints of the hands and feet
or the wrists. The revised criteria categories were re-
weighted. The 10 cases were re-scored and re-ranked.
The resultant revised rank ordering was deemed appro-
priate. The revised categories and their associated
weights are shown in Table 2.
Post–consensus meeting modifications. The draft
criteria set was reviewed with Phase 1 and 2 participants
at a second in-person meeting. The revisions described
below were recommended.
Consideration of erosions. Due to the desire to
classify and treat individuals with RA early in their
disease course in order to prevent damage, the presence
of erosions should not be included within the classifica-
tion criteria. However, the criteria do need to be appli-
cable across the spectrum of the potential disease
course. Further discussion of this issue was necessary,
and was addressed in the third phase of the project (1).
Pattern and extent of joint involvement. Based on
their similar weightings, the categories of small joint
involvement that referred to symmetric versus asymmet-
Table 1. Initial criteria, their respective categories, and initial
weights assigned to each category*
Criterion and category Score
Joint involvement (pattern and distribution)
1 medium-large joint 0.0
Asymmetric medium-large joints (at least 2 joints) 12.3
Symmetric medium-large joints (at least 2 joints) 20.0
13 small joints (hands/feet or wrists) 26.2
4 asymmetric small joints (hands/feet or wrists) 35.4
4 symmetric small joints (hands/feet or wrists) 36.9
Serology (ACPA or RF)
RF negative and ACPA negative 0.0
Low-positive (RF positive and/or ACPA positive) 27.0
High-positive (RF positive and/or ACPA positive) 43.1







* Scores from each criterion are summed to derive the total score,
which represents the probability of developing rheumatoid ar-
thritis (RA). ACPA  anticyclic citrullinated protein; RF  rheu-
matoid factor; CRP  C-reactive protein; ESR  erythrocyte sedi-
mentation rate.
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ric involvement were combined in a single category:
“4–10 small joints” (Table 2).
Serology. Informed by a systematic literature re-
view of the diagnostic properties of ACPA and RF
assays (9) and input from assay makers and researchers
in the field (10,12), the serology task force recom-
mended that the local laboratory and assay upper limit
of normal (ULN) be used to categorize serologic results
as follows: normal  less than or equal to the ULN;
low-level positive  higher than the ULN but 3 times
the ULN; and high-level positive  3 times the ULN.
If the result was not available, it should be regarded as
normal or negative. Further, patients should be scored
only if there are results available for at least 1 serologic
test. This recommendation may be revised once stan-
dardized units become available (for ACPA) or are
universally employed (for RF).
Acute-phase response. Participants agreed that if a
test were unavailable, the result should be regarded as
normal. As with serology, patients should be scored only
if results are available for at least 1 acute-phase reactant.
Duration. Expert panel participants noted that in
performing the paired discrete choice exercise, they had
used the midpoint of the 4–8-week category rather than
the extreme ends of the range in making their choices.
Thus, this criterion was simplified to duration 6 weeks
versus 6 weeks.
The decision analytic software program that was
used can accommodate alterations in the categories, as
was necessary for combining categories in the joint
involvement criterion and the duration criterion. Subse-
quent analysis of the cases included in the in-person
consensus meeting confirmed that decisions implied
from the combined categories were consistent with the
decisions made at the meeting. The revised criteria set
and associated weights are shown in Table 3.
Assessment of interrater reliability of case cate-
gorization. The remaining unused 56 patient case sce-
narios were reviewed for presence of the 2 mandatory
criteria outlined above. Two cases were excluded (for
both, another inflammatory arthritis condition was more
likely). The remaining 54 cases were independently
categorized within each of the 4 domains by 7 individuals
(4 steering committee members and 2 volunteers unfa-
miliar with the project to date). For cases in which the
ULN for the laboratory had not been provided, that
information was obtained whenever possible. Where
either a test result or the ULN value was not provided,
the raters were asked to consider the value to be normal.
Categorization discordance arose largely from
the use of the originally developed standardized tem-
plate, which failed to include pertinent information on
the subsequently identified criteria and categories. Re-
finements to the criteria and category definitions were
Table 3. Final revised categories and weights at end of Phase 2*
Criterion and category Score
Joint involvement (pattern and distribution)
1 medium-large joint 0
Asymmetric medium-large joints (at least 2 joints) 10.2
Symmetric medium-large joints (at least 2 joints) 16.1
13 small joints (hands/feet or wrists) 21.2
410 small joints (hands/feet or wrists) 28.8
410 symmetric small joints (hands/feet or wrists) 29.4
10 joints including hands/feet or wrists 50.8
Serology (ACPA or RF)
RF negative and ACPA negative 0
Low-positive (RF positive and/or ACPA positive) 22.0
High-positive (RF positive and/or ACPA positive) 33.9






* Scores from each criterion are summed to derive the total score,
which represents the probability of developing rheumatoid arthritis
(RA). ACPA  anticyclic citrullinated protein; RF  rheumatoid
factor; CRP  C-reactive protein; ESR  erythrocyte sedimentation
rate.
Table 2. Revised categories and weights after inclusion of additional
joint involvement category*
Criterion and category Score
Joint involvement (pattern and distribution)
1 medium-large joint 0.0
Asymmetric medium-large joints (at least 2 joints) 10.1
Symmetric medium-large joints (at least 2 joints) 16.0
13 small joints (hands/feet or wrists) 21.0
4 asymmetric small joints (hands/feet or wrists) 27.7
410 symmetric small joints (hands/feet or wrists) 29.4
10 joints including hands/feet or wrists 50.5
Serology (ACPA or RF)
RF negative and ACPA negative 0.0
Low-positive (RF positive and/or ACPA positive) 21.8
High-positive (RF positive and/or ACPA positive) 33.6







* Scores from each criterion are summed to derive the total score,
which represents the probability of developing rheumatoid ar-
thritis (RA). ACPA  anticyclic citrullinated protein; RF  rheu-
matoid factor; CRP  C-reactive protein; ESR  erythrocyte sedi-
mentation rate.
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made, after which consensus categorization (100%
agreement) was achieved for all cases.
Assessment of face and construct validity. Using
the consensus categorizations and associated weights
shown in Table 3, the 54 cases were scored. The resulting
scores ranged from a low of 15.3 to a high of 100.0
(Figure 3). The resulting rank order, based on these
scores, was reviewed by 31 Phase 1 and Phase 2 partic-
ipants. They identified no substantive concerns, indicat-
ing face validity of the scoring system. The proportion
who indicated that they would institute MTX or another
DMARD due to a concern about risk for “developing
RA,” and that they would enroll the patient into a
clinical trial of a new biologic agent with inherent risks,
are shown in Figure 3. As expected, the proportion of
cases for which the rheumatologists would initiate MTX
or another DMARD was greater than that for which
they would recommend entry into a clinical trial of a
biologic agent. The slight decrease in initiation of MTX
or enrollment in a clinical trial at a score of 64–65
occurred for 2 cases that had high-positive serology, but
relatively few joints involved. Overall, with this excep-
tion, both proportions increased with increasing proba-
bility of RA, supporting the construct validity of the
scoring system.
DISCUSSION
Using an evidence-based consensus methodol-
ogy, an expert panel of rheumatologists identified 6
criteria that are important in determining the probability
that a patient with undifferentiated inflammatory arthri-
tis will develop persistent and/or erosive inflammatory
arthritis that we currently consider to be RA. Two
criteria were deemed essential: evidence of expert-
assessed clinical joint swelling, indicating synovitis, in at
least 1 joint and the absence of another condition that
would better explain the patient’s presentation. The
remaining 4 criteria (pattern and extent of joint involve-
ment, serology [ACPA and/or RF], acute-phase re-
sponse [ESR and/or CRP], and duration of synovitis)
each contributed differently to the probability of devel-
oping RA. The relative weighting of these 4 criteria and
their subcategories was determined using a new meth-
odology with a consensus-based decision analytic soft-
ware program (3). Applying the derived scoring system
to a set of case scenarios produced a rank ordering close
to the order determined by the clinical judgment of the
group, and was consistent with the data-derived outcome
of Phase 1, providing a degree of face and construct
validity.
In many countries, imaging techniques, e.g., ul-
trasound and magnetic resonance imaging, are being
used to evaluate synovitis. However, the predictive va-
lidity of synovitis detected only by imaging, and by
non-experts, in the absence of clinically obvious joint
swelling remains unclear. Thus, the expert panel recom-
mended that “definite” synovitis in at least 1 joint be
determined based on evidence of joint swelling on
Figure 3. Proportion of respondents who would prescribe methotrexate (MTX) or another
disease-modifying antirheumatic drug and proportion who would enroll the patient in a random-
ized controlled trial (RCT) of a biologic therapy, for clinical scenarios arranged from lowest to
highest probability of “developing rheumatoid arthritis” based on the total score derived from the
Phase 2 criteria set.
ACR/EULAR CLASSIFICATION CRITERIA FOR RA, PHASE 2 METHODOLOGY 2589
clinical assessment by an expert assessor. Whenever
possible, this should be a rheumatologist or other phy-
sician with expertise in autoimmune rheumatic diseases.
Given the required presence of swelling in at least 1
joint, and the inherent imprecision of clinical determi-
nation of joint swelling, the expert panel recommended
that joint involvement (i.e., number and pattern) should
be assessed based on joint swelling or tenderness on
clinical examination. Imaging modalities could be used
to confirm these clinical findings.
Fulfillment of the second mandatory criterion,
that clinical presentation was not better explained by
another diagnosis, also requires clinical expertise. Pa-
tients in whom signs and symptoms may be explained by
more than one inflammatory arthritis condition should
not be assessed using these criteria until further evalu-
ation has taken place. It was not the group’s intent to
imply that specific investigations should be performed to
rule in or rule out alternative inflammatory arthritides
or other diagnoses. Rather, the intent was to ensure that,
in the physician’s opinion, no other condition better
explain the situation.
The one patient factor that was surprisingly not
included was duration of morning stiffness. Many rheu-
matologists hold strong opinions regarding the value of
this patient-reported symptom in making a diagnosis and
determining a management approach. However, in the
Phase 1 study, duration of morning stiffness 1 hour
versus 1 hour did not discriminate between patients
who did and those who did not receive MTX within a
year of diagnosis. Furthermore, while this symptom can
reflect the burden of inflammation, on an individual
patient level it does not discriminate among the inflam-
matory arthritides, or even between inflammatory and
noninflammatory disease. Thus, morning stiffness was
not included.
During the in-person consensus meeting, expert
panel members agreed that symmetry of joint involve-
ment was important in determining the probability of
RA. However, the weights derived for symmetric versus
asymmetric involvement, for medium-large joints as well
as for small joints, were remarkably similar. This sug-
gests that our decision-making is not based on symmetry
once other factors, e.g., the number and type of joints
involved and the serologic results, are taken into consid-
eration. Again, this was consistent with findings in the
Phase 1 analyses.
Phase 2 used a new methodology to derive con-
sensus among expert clinicians, which is more transpar-
ent and flexible than usual Delphi consensus ap-
proaches. This method is also cognitively and timewise
less burdensome than other methods, with a high degree
of validity and reliability (3). As with all consensus
methodologies, the result is dependent on the expertise
and information of the expert panel.
In summary, Phase 2 utilized a novel consensus
methodology in which decision analysis was integrated
to derive a preliminary set of criteria and criteria
categories, with associated weights representing their
relative importance. The process was informed by Phase
1 data and results and the published literature, wherever
possible. Together with Phase 1, this work informed the
final phase of criteria development, outlined in the
companion report (1), in which the final criteria set,
including the cut point to be used to define definite RA,
were determined and preliminary validation performed.
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